ARCHIVES

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

NHIS Cancer Control Supplement To Survey 52,000

October 4, 1985

NIH Challenge Grant Announcement

March 6, 2009

In Brief: Cancer Act Renewal Nears, Appropriations Bills Lag; Interim Funding Likely For ’83 Fiscal Year

September 24, 1982

Southern Gets Two More Contracts Totaling 44.5 Million From NCI

June 14, 1974

Amgen Cancels Rilotumumab Trials in Gastric Cancer

December 26, 2014

Drug Combination Tested For B.C. Brain Metastases

January 25, 2008